Literature DB >> 3516688

Technical aspects and clinical correlations of the serum bactericidal test.

H C Standiford, B A Tatem.   

Abstract

A review of the studies using 50% human serum as a diluent for the serum bactericidal test has shown correlations with patient outcome. Human serum used as diluent of the patient's serum appears to be essential because of high protein binding of some antibiotics. An inoculum of 10(5)-10(6) bacteria/ml and a bactericidal criteria of 99.9% killing are technical aspects that have gained popularity. Careful timing of serum collection for the assay is important. Neither the macrotube nor microtiter techniques are entirely satisfactory. The latter method, however, has the advantage of being more reproducible than the macrotube method, less cumbersome and requiring less serum. Preliminary guidelines for performing and interpreting the test are provided. Future research should be directed toward making the microtiter technique more sensitive for identifying antibiotic tolerance, developing effective methods to eliminate the need for human serum as a diluent and obtaining more clinical correlations.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3516688     DOI: 10.1007/bf02013474

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN: 0722-2211            Impact factor:   3.267


  38 in total

1.  Significance of serum bactericidal activity in gram-negative bacillary bacteremia in patients with and without granulocytopenia.

Authors:  J P Sculier; J Klastersky
Journal:  Am J Med       Date:  1984-03       Impact factor: 4.965

2.  Variables in demonstrating methicillin tolerance in Staphylococcus aureus strains.

Authors:  K Ishida; P A Guze; G M Kalmanson; K Albrandt; L B Guze
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

3.  Postantibiotic suppression of bacterial growth.

Authors:  R W Bundtzen; A U Gerber; D L Cohn; W A Craig
Journal:  Rev Infect Dis       Date:  1981 Jan-Feb

Review 4.  The role of the microbiology laboratory in the diagnosis and antimicrobial treatment of infective endocarditis.

Authors:  J A Washington
Journal:  Mayo Clin Proc       Date:  1982-01       Impact factor: 7.616

5.  Intravenous followed by oral antimicrobial therapy for staphylococcal endocarditis.

Authors:  R H Parker; B E Fossieck
Journal:  Ann Intern Med       Date:  1980-12       Impact factor: 25.391

6.  Multiple-dose pharmacokinetics of imipenem-cilastatin.

Authors:  G L Drusano; H C Standiford; C Bustamante; A Forrest; G Rivera; J Leslie; B Tatem; D Delaportas; R R MacGregor; S C Schimpff
Journal:  Antimicrob Agents Chemother       Date:  1984-11       Impact factor: 5.191

7.  Lack of in vivo and in vitro bactericidal activity of N-formimidoyl thienamycin against enterococci.

Authors:  R Auckenthaler; W R Wilson; A J Wright; J A Washington; D T Durack; J E Geraci
Journal:  Antimicrob Agents Chemother       Date:  1982-09       Impact factor: 5.191

8.  Method of reliable determination of minimal lethal antibiotic concentrations.

Authors:  R D Pearson; R T Steigbigel; H T Davis; S W Chapman
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

9.  The rate of bactericidal action of penicillin in vitro as a function of its concentration, and its paradoxically reduced activity at high concentrations against certain organisms.

Authors:  H EAGLE; A D MUSSELMAN
Journal:  J Exp Med       Date:  1948-07       Impact factor: 14.307

10.  A new type of penicillin resistance of Staphylococcus aureus.

Authors:  L D Sabath; N Wheeler; M Laverdiere; D Blazevic; B J Wilkinson
Journal:  Lancet       Date:  1977-02-26       Impact factor: 79.321

View more
  6 in total

1.  MIC and serum bactericidal activity of clindamycin against methicillin-resistant and -sensitive staphylococci.

Authors:  S Lemmen; A Kropec; I Engels; A Busse; F D Daschner
Journal:  Infection       Date:  1993 Nov-Dec       Impact factor: 3.553

2.  Comparative serum bactericidal activities of three doses of ciprofloxacin administered intravenously.

Authors:  M Dan; F Poch; C Quassem; R Kitzes
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

3.  Pharmacokinetics of sparfloxacin and serum bactericidal activity against pneumococci.

Authors:  M Trautmann; M Ruhnke; K Borner; J Wagner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

4.  Ex vivo pharmacodynamic study of piperacillin alone and in combination with tazobactam, compared with ticarcillin plus clavulanic acid.

Authors:  P Van der Auwera; V Duchateau; C Lambert; M Husson; M Kinzig; F Sörgel
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

5.  Bactericidal activity of ciprofloxacin compared with that of cefotaxime in normal volunteers.

Authors:  H C Standiford; G L Drusano; A Forrest; B Tatem; K Plaisance
Journal:  Antimicrob Agents Chemother       Date:  1987-08       Impact factor: 5.191

6.  Serum bactericidal activity after administration of four cephalosporins in healthy volunteers.

Authors:  S Lemmen; A Kropec; I Engels; A Busse; F D Daschner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-11       Impact factor: 3.267

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.